Navigation Links
Misonix Adds Industry Veteran To Management Team
Date:7/12/2012

FARMINGDALE, N.Y., July 12, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced the addition of industry veteran, Christopher A. DeNicola, to its sales management team.  Mr. DeNicola joined the Company on July 1, 2012, as Senior Director of Sales – North America for its neurosurgery, spine surgery and orthopedic surgery products.  Products in this category are the SonaStar® Ultrasonic Surgical Aspiration System and the BoneScalpel™ Ultrasonic Bone Cutting System.

Mr. DeNicola, who is degreed in Management, has almost 20 years of successful sales management experience in Orthopedic Surgery, Neurosurgery and Podiatric Surgery, with a heavy concentration in Spine Surgery.  He has worked with direct, distributor and hybrid sales organizations.  Previous employers included EBI (a Biomet Company), Small Bone Innovations and Scient'x USA.  The Company expects that Mr. DeNicola's presence will add measurably to the rapid expansion of its Neuro/Orthopedic sales organization.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.  Use of this product is being rapidly accepted by spine and skull-based surgeons on a worldwide basis.

"We are very pleased to add a sales executive of Chris DeNicola's experience and stature to our growing domestic sales organization," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "His knowledge of distributors, combined with his established relationships with physician thought leaders in our target markets, should prove to be quite valuable in rapidly expanding our domestic market presence."

About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact:

Lytham Partners, LLCRichard Zaremba

Robert Blum, Joe Dorame, Joe Diaz631-694-9555

602-889-9700invest@misonix.com 

mson@lythampartners.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Exhibits at Major Worldwide Spine Conference
2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
3. Misonix Announces New Distribution Agreement For Panama
4. CSS Health Technologies Hires Industry Leader as New Senior Vice President of Sales
5. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
6. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
7. Global Kidney Cancer Drugs Industry
8. Global Imaging Agents Industry
9. Global Veterinary Vaccines Industry
10. Global Clinical Diagnostics Automation Industry
11. Global Growth Factors (Blood And Tissue) Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
(Date:12/2/2016)... 2016 Research and Markets has announced ... Cancer - Technologies, Markets and Companies" to their offering. ... , , ... cancer The market value of drug delivery technologies and ... 2015-2025 are given according to organs involved and the types of ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, ... expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural ... students and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee ...
(Date:12/2/2016)... ... 2016 , ... FlexiSpot, a trusted name in sit-stand solutions ... for all of the company’s desktop riser products. A simple application form and ... FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
Breaking Medicine News(10 mins):